Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials - Scorecard - MDSpire

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials

  • By

  • Shuo Zhao

  • Miaoqin Wu

  • Jingxiang Zhong

  • Baihua Chen

  • Zongming Song

  • Zhang Ming

  • Quanhong Han

  • Suqin Yu

  • Hong Wang

  • Songtao Yuan

  • Jin Yao

  • Mingwei Zhao

  • Xiaohong Meng

  • Feng Wang

  • Jing Lou

  • Yanli Liu

  • Haomin Huang

  • Qinghong Zhou

  • Yuyu Xu

  • Hong Dai

  • Xiaorong Li

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of the safety and effectiveness of monoclonal antibody 601 targeting anti-VEGF for treating macular oedema associated with retinal vein occlusion: results from two phase IIa randomized clinical trials

At a Glance

CategoryDetail
ConditionMacular oedema associated with retinal vein occlusion (RVO)
Key MechanismsInhibition of vascular endothelial growth factor (VEGF)
Target PopulationPatients aged ≥18 years with macular oedema secondary to branch RVO or central RVO
Care SettingMulticentre, randomised, double-blinded clinical trials

Key Highlights

  • 601 provided similar vision and anatomic improvement to ranibizumab over 52 weeks.
  • Both treatments were administered via intravitreal injection every 4 weeks.
  • 601 demonstrated a favourable safety profile compared to ranibizumab.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of RVO confirmed by clinical examination and imaging.

Management

  • Intravitreal injections of anti-VEGF agents are first-line treatment for macular oedema secondary to RVO.

Monitoring & Follow-up

  • Monitor best-corrected visual acuity (BCVA) and central retina thickness (CST) at regular intervals.

Risks

  • Potential ocular and non-ocular adverse events associated with anti-VEGF therapy.

Patient & Prescribing Data

Patients with foveal centre-involved macular oedema following RVO diagnosis within 12 months.

Patients received either 601 (1.25 mg/eye) or ranibizumab (0.5 mg/eye) with standardised retreatment criteria.

Clinical Best Practices

  • Follow CONSORT guidelines for reporting clinical trials.
  • Obtain informed consent before initiation of study procedures.

Related Resources & Content

Original Source(s)

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials

  • by Shuo Zhao, Miaoqin Wu, Jingxiang Zhong, Baihua Chen, Zongming Song, Zhang Ming, Quanhong Han, Suqin Yu, Hong Wang, Songtao Yuan, Jin Yao, Mingwei Zhao, Xiaohong Meng, Feng Wang, Jing Lou, Yanli Liu, Haomin Huang, Qinghong Zhou, Yuyu Xu, Hong Dai, Xiaorong Li

  • July 1, 2026

Related Content

Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies

New CEO for Optos

Optos appoints Alexandre Montague as Chief Executive Officer

  • June 26, 2026

  • 2 min
Emerging Trends in Intraocular Tamponade